Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse

Robson G. Dossa, Tanya Cunningham, Daniel Sommermeyer, Indira Medina-Rodriguez, Melinda A. Biernacki, Kimberly Foster, Marie Bleakley

Blood (2018) 131 (1): 108–120.

https://doi.org/10.1182/blood-2017-07-791608

Published: 2018

Includes: Supplemental data

Journal Articles

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Cameron J Turtle, MBBS, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Laila-Aicha Hanafi, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 184.

https://doi.org/10.1182/blood.V126.23.184.184

Published: 2015

Journal Articles

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 3773.

https://doi.org/10.1182/blood.V126.23.3773.3773

Published: 2015

Journal Articles

Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

Cameron J Turtle, MBBS, PhD, Daniel Sommermeyer, PhD, Carolina Berger, MD, Michael Hudecek, MD, David M Shank, Natalia N Steevens, BS, Tanya M Budiarto, BSc, Mandana Karimi, MS, Colette N Chaney, RN, Anna Marie DeVito, RN, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R Riddell, MD, David G Maloney, MDPhD

Blood (2014) 124 (21): 384.

https://doi.org/10.1182/blood.V124.21.384.384

Published: 2014

Journal Articles

Selecting T-Cell Subsets for Adoptive T-Cell Therapy to Optimize Potency and Persistence

Stanley Riddell, MD, Cameron Turtle, Michael Hudecek, MD, Daniel Sommermeyer, Ph.D, Michael C. Jensen, MD

Blood (2013) 122 (21): SCI-39.

https://doi.org/10.1182/blood.V122.21.SCI-39.SCI-39

Published: 2013

Journal Articles

Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity

Susanne Wilde, Daniel Sommermeyer, Bernhard Frankenberger, Matthias Schiemann, Slavoljub Milosevic, Stefani Spranger, Heike Pohla, Wolfgang Uckert, Dirk H. Busch, Dolores J. Schendel

Blood (2009) 114 (10): 2131–2139.

https://doi.org/10.1182/blood-2009-03-209387

Published: 2009

Journal Articles

Generating of Human CD4 + and CD8 + T Lymphocytes toward NY-ESO-1 by T Cell Receptor (TCR) Modification and Transduction for Adoptive TCR Gene-Transfer

Holger Krönig, MD, Kathrin Hofer, Daniel Sommermeyer, Christian Peschel, MD, Wolfgang Uckert, Helga Bernhard, MD

Blood (2008) 112 (11): 3533.

https://doi.org/10.1182/blood.V112.11.3533.3533

Published: 2008

Journal Articles

Redirecting Human T Lymphocytes toward Tumor-Associated Antigens by T Cell Receptor (TCR) Replacement.

Julia Neudorfer, Daniel Sommermeyer, Christian Peschel, MD, Thomas Blankenstein, PhD, Wolfgang Uckert, PhD, Helga Bernhard, MD

Blood (2006) 108 (11): 3711.

https://doi.org/10.1182/blood.V108.11.3711.3711

Published: 2006

NARROW

Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

Selecting T-Cell Subsets for Adoptive T-Cell Therapy to Optimize Potency and Persistence

Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity

Generating of Human CD4 + and CD8 + T Lymphocytes toward NY-ESO-1 by T Cell Receptor (TCR) Modification and Transduction for Adoptive TCR Gene-Transfer

Redirecting Human T Lymphocytes toward Tumor-Associated Antigens by T Cell Receptor (TCR) Replacement.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only